ST. PAUL, Minn. & ST. LOUIS--(BUSINESS WIRE)--Kindeva Drug Delivery (“Kindeva”) and Meridian Medical Technologies (“Meridian”) announced today the completion of the transaction to combine the two ...

The global drug-device combination products market is projected to experience a compound annual growth rate (CAGR) of approximately 9% during the forecast period. This growth is largely driven by the ...

Australia’s TGA has opened a consultation on drug-device combination products to help sponsors understand the regulatory pathway through which their products will likely pass since these combination ...

In January 2022, the U.S. Food and Drug Administration (FDA) released finalized guidance on premarket pathways for combination products. While the guidance is not binding, it provides industry ...

While the concept of a combination product is not new, these unique healthcare products (drug plus device, biological plus device, drug plus biological product, or drug plus device plus biological ...

Marketing efforts take vastly different shapes in the pharmaceutical and medical device industries. In pharmaceutical marketing, product brands reign supreme, as demonstrated by household names such ...

Abbott is a prominent key player in the global drug device combination products market. Abbott's Medical Devices segment delivers a combination of products, particularly in high-impact areas such as ...

Genus Medical Technologies, LLC v. FDA legal case leads to agency-wide review and reclassification of eye cups, eye droppers, and ophthalmic dispensers “While we were surprised by the FDA’s position ...

The global drug device combination products market is expected to reach $115.1 billion by 2019, growing at a compound annual growth rate of 7.9 percent, according to a news release. In 2012, the ...

The continuous evolution of electronic devices and systems necessitates rigorous performance evaluation, comprehensive testing, and robust simulation strategies. These activities are central to ...